The company has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet.
The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization.
“Our new, global partnership has the potential of expanding Bactiguard’s current license business significantly and making a substantial contribution to our license revenues, both in the near term and in a longer perspective. It also confirms the value of the Bactiguard technology in a new application and global context, which makes me both happy and proud,” says Christian Kinch, CEO.
CE marked in December 2018
Orthopedic trauma implants with Bactiguard’s infection preventive technology were CE marked in December 2018 and will be used as a reference in the process of obtaining regulatory clearance.
In 2018, Zimmer Biomet generated net sales of close to USD 8 billion.
Photo of Christian Kinch: Bactiguard